For years, Italy has carried a peculiar reputation in MedTech circles: admired for its surgeons, respected for its hospitals, but quietly avoided whenever the conversation turned to reimbursement.
Executives would talk about the country with the tone reserved for Byzantine tax codes or ancient riddles — fascinating, important, but almost impossible to navigate.

“Italy? Fantastic clinicians. Impossible system.”

It was the industry’s favourite myth.
And yet, while nobody was looking, Italy began to change.

Between 2020 and 2025, a quiet revolution unfolded inside its healthcare system — not with the theatre of Germany’s DiGA, nor the bureaucratic choreography of France’s LPPR reforms, but with something subtler and arguably more consequential: the layering of four reimbursement pathways that now give MedTech, diagnostics and digital health innovators more options — and more leverage — than at any point in the last twenty years.

A new national HTA programme (PNHTA) is reshaping how evidence is reviewed.
Regions such as Lombardy, Emilia-Romagna and Veneto are rewriting procurement rules in ways that reward innovation instead of resisting it.
National mechanisms such as LEA updates, DRG recalibration, and Law 648/96 early-access funding are offering durable reimbursement where none existed before.
And Italy’s emerging legislation on digital therapeutics hints at a reimbursement future the country has never previously contemplated.

The truth is simple:

Italy is no longer the black box of European reimbursement. It is becoming one of its most strategically interesting markets — if you understand how the system now works.

What follows is not another shallow “country overview,” nor a recycled checklist of agencies and acronyms.
It is a scientific, evidence-based, deeply practical guide to the real routes to reimbursement — national, regional and hybrid — backed by real examples, real decision-making logic, and a clear explanation of how MedTech and IVD companies can succeed in Italy in 2025–2026.

Why Italy Looks Impossible (But Isn’t)

If you ask many global MedTech and IVD companies why they hesitate to launch in Italy, the answer often sounds like this:

“It’s just too opaque. The rules change by region. There’s no national code. Reimbursement is slow. We don’t understand who decides.”

And yes — for many years they weren’t wrong. Italy did appear nearly impossible: a complex federal-style health system with 20 regions, each acting with substantial autonomy; national agencies with overlapping mandates; and reimbursement paths designed more for pharmaceuticals than for advanced diagnostics or digital health tools.

But here’s the truth: Italy isn’t broken — it’s evolving.
And that evolution means that what looked like “chaos” is increasingly structured, predictable, and — with the right approach — highly accessible.

The Illusion of “No Pathway”

One of the most persistent myths is that a company simply cannot get reimbursement for an IVD or MedTech in Italy because there is “no pathway”. But in reality:

The national agency AGENAS (Agenzia Nazional per i Servizi Sanitari Regionali) now runs a national HTA programme for medical devices covering 2023-2025, officially published on 14 April 2025. agenas.gov.it+2agenas.gov.it+2
National laws such as Law 648/96 (initially for early-access medicinal products) demonstrate that Italy can provide national reimbursement for “non-standard” technologies; the mechanism exists. journals.aboutscience.eu+2intexo.it+2
Regionally-driven procurement is real. Regions like Lombardy, Veneto, Emilia-Romagna have internal HTA, internal budgets, and tenders where innovation can win.

Why the “Impossible” Label Still Persists

Despite progress, several features make Italy feel difficult:

Decentralised decision-making: Each region has its own health authority, budget, procurement cycle, and innovation appetite.
Mixed funding mechanisms: Unlike some countries with standard national tariffs for devices, Italy uses regional tenders, hospital budgets, special funds, and DRG adjustments — which means you must map multiple routes rather than assume “one national code”.
Evidence expectations differ: Italy emphasises organisational, workflow, budget-impact and real-world evidence more than double-blind RCTs (especially for diagnostics). If your dossier is prepared in a pharma-style only, you risk missing the mark.
Terminology and coding remain in flux: Italy still uses older procedure codes (e.g., ICD-9-CM) and device/IVD tariff sets are less harmonised than drugs. This leads to confusion and extra work.
Visibility is low: Many companies don’t know about PNHTA, regional HTA units, or early access funds — so they default to assuming nothing exists.

Why This Section Matters for You

Because your job is precisely to make sense of the “impossible”, and position your clients ahead of the curve.

When you show a diagnostics company:

“Yes, Italy looks hard — but actually there are four identifiable, strategic pathways you can plan for.”
“Yes, there are 20 regions — but once you succeed in 2-3 you create a domino effect.”
“Yes, the tariffs may not be obvious — but workflow, budget impact, procurement and HTA are the levers you can pull.”

…then you turn “Italy as an after-thought” into “Italy as a strategic early-launch market”.

In the next section, we’ll map how the Italian health system actually works, clarifying national vs regional power, procurement sources, and decision-making bodies.

How Italy’s Health System Really Works:

National Rules, Regional Power, and the People Who Actually Say “Yes”**

If Italy looks opaque from the outside, it is because most companies misunderstand the fundamental shape of the system. Italy is not a classic centralised model like France, nor a fully decentralised one like Spain. It is something in between — a hybrid federation where national institutions set the rules, but the real decisions are often made hundreds of kilometres away from Rome.

To succeed in Italy, a MedTech or diagnostics company must understand one simple truth:

Reimbursement is national.
Adoption is regional.
Procurement is local.
And evidence flows between all three.

Let’s map the landscape clearly.

National Level — The Rule-Makers and Gatekeepers

A. Ministry of Health (Ministero della Salute)

Sets national policies, approves updates to the LEA (Livelli Essenziali di Assistenza), and oversees national funds, including early-access mechanisms.

B. AGENAS (Agenzia Nazionale per i Servizi Sanitari Regionali)

This is the emerging powerhouse.

Runs the National HTA Programme for Medical Devices (PNHTA)
Publishes national HTA reports (e.g., the 2025 robotic surgery report)
Coordinates with regional HTA committees
Provides methodological guidance for economic and organisational evaluation

A positive PNHTA assessment doesn’t automatically guarantee reimbursement — but it dramatically accelerates adoption because regions use it as a scientific and political anchor for procurement decisions.

This is exactly how robotics gained national legitimacy in 2025.

C. AIFA (Agenzia Italiana del Farmaco)

Primarily responsible for pharmaceuticals, but historically manages:

Law 648/96 early-access funding
National registers
Governance of high-cost therapies

For diagnostics and MedTech, AIFA plays a smaller (but non-zero) role — particularly when diagnostics fall into special funding categories or when linked to therapies funded under 648/96.

Regional Level — The Real Power Centres

Italy’s 20 regions are the most important actors for IVD and MedTech.

Each region manages:

its own health budget
procurement cycles
innovation committees
regional HTA units
hospital networks

This explains why Tuscany could independently launch a €2.63 million tender for rapid AST testing across nine hospitals, without waiting for any national tariff.

It also explains why:

Lombardy is consistently the fastest adopter of robotics, molecular diagnostics and AI
Emilia-Romagna is the strongest evidence-driven region
Veneto is the most efficient in outpatient diagnostics reimbursement
Lazio is now investing over €110 million in biotech competitiveness

In practical terms:

If two regions decide to adopt your technology, the rest often follow within 12–24 months.
Italy moves by domino effect, not by decree.

Local Level — The Hospital Trusts Who Actually Buy

At the end of the chain are the Aziende Ospedaliere and Aziende Sanitarie Locali (ASL/ATS/USL) — the operational health authorities who:

run the hospitals
negotiate local procurement
implement new diagnostics
generate real-world evidence
decide which devices fit their workflows

In Tuscany’s rapid AST example, the nine hospitals involved were part of the ESTAR network — a centralised regional procurement body that coordinates purchasing for all Tuscan hospital trusts.

This is Italy’s operational reality:

Procurement is centralised regionally
Deployment is implemented locally
Evidence is generated patient-by-patient in hospital labs and wards

Your success, therefore, depends not just on national policy, but on Italian clinicians, lab directors and hospital administrators who see your technology improving care.

How Decisions Flow in Italy

Here is how a diagnostic or MedTech technology typically moves through Italy:

STEP 1 — National signals

PNHTA report → LEA discussion → digital health legislation draft → scientific society endorsement.

STEP 2 — Regional evaluation

Regional HTA → budget prioritisation → clinical network discussions → inclusion in tender pre-planning.

STEP 3 — Procurement mechanisms

Centralised regional tender → framework agreements → direct purchase for emerging tech → innovation pilots.

STEP 4 — Hospital-level implementation

Lab validation → workflow integration → training → RWD generation → cost–consequence evaluation.

STEP 5 — National reinforcement

If evidence is strong, regions request:

DRG recalibration
LEA inclusion
national funding streams (for rare disease, screening, oncology, etc.)

This is how a single regional tender can eventually influence national reimbursement policy.

Why This Structure Matters for Your Strategy

Because it changes everything.

Most companies fail in Italy because they begin with the wrong question:

“How do we get a national code?”

The right question is:

“How do we secure regional adoption and national legitimacy at the same time?”

You do that through:

PNHTA submissions
targeted pilot sites
evidence that speaks to Italian workflow pressures
regional stakeholder mapping
economic modelling based on Italian cost structures
using early-access pathways (like Law 648/96)
and building credibility inside 2–3 early adopter regions.

Once you understand the interplay between national rule-makers, regional fund managers, and hospital implementers, Italy stops being a mystery and becomes one of the most predictable MedTech ecosystems in Europe.

The Four Proven Reimbursement Pathways in Italy

(Backed by Real Case Studies)**

If the architecture of Italian health policy explains who decides, the four reimbursement pathways explain how money moves. And in Italy — unlike in France, Germany or the UK — the routes are not stacked sequentially but run in parallel.
Understanding this is the difference between losing two years in regulatory limbo and gaining a rapid first-mover advantage.

These are the four pathways every MedTech, IVD and digital health innovator must understand.

PATHWAY 1 Regional Procurement:

Italy’s Real Engine of Adoption**

For most technologies — particularly diagnostics, rapid tests, digital tools and workflow innovations — regional procurement is the fastest, most reliable entry route.

Each region runs its own:

tenders,
framework agreements,
technical evaluations,
and capital/expenditure budgets.

This means you can enter Italy without a national code, and without waiting for a national tariff.
If you can show that your technology improves workflow, reduces hospital days, accelerates diagnosis, or prevents complications, regions can fund you directly.

What Italy values in this pathway

Laboratory efficiency
Reduced ICU stay
Faster clinical decision-making
Antibiotic optimisation
Prevention of costly complications
Strengthening emergency/urgent care
Proven cost–consequence impact

Real Example: Tuscany’s Rapid AST Tender (2024)

In 2024, the Region of Tuscany — through its procurement body ESTAR — issued a €2.63 million multi-year tender for rapid antibiotic susceptibility testing (AST) across nine hospitals.
It covered:

rapid AST instruments,
consumables,
and multi-annual supply contracts.

Importantly:

No national code existed.
No national tariff was needed.
The tender proceeded because the clinical and organisational case was strong: faster AST reduces mortality, antibiotic misuse and ICU length of stay.

This is Route 1 in its purest form: evidence → regional decision → funded adoption.

PATHWAY 2 National Tariffing:

LEA, DRG Recalibration, and the “Formal” Reimbursement Layer**

While procurement drives early adoption, Italy also offers national mechanisms for durable, structural reimbursement, especially for diagnostics used in:

hospital admissions,
emergency medicine,
oncology,
women’s health,
rare diseases.

There are two powerful tools here.

A. LEA (Livelli Essenziali di Assistenza)

The LEA is Italy’s list of essential nationally funded services — the closest analogue to:

LPPR (France),
EBM + G-BA (Germany),
National Tariff (UK).

If your diagnostic or digital tool enters the LEA list, every region must fund it.

Recent LEA updates have included:

non-invasive prenatal screening (NIPS),
genomic oncology testing via specialist centres,
high-need infectious disease diagnostics.

B. DRG Recalibration / Add-On Payments

If your device is used in inpatient care — for surgery, sepsis, cardiology, orthopaedics — you can secure reimbursement by recalibrating the DRG tariff attached to the procedure.

This is Italy’s version of:

NUB → DRG integration (Germany),
“Innovation payments” (UK),
“Valorisation forfaitaire” (France).

Real Example: Robotic Surgery DRG Adjustments

The 2025 AGENAS National HTA Report on Robotic Surgery documented:

fewer complications,
shorter length of stay,
lower readmissions,
strong organisational advantages,
and better patient outcomes.

Regions used these findings to justify:

higher reimbursements for specific DRGs,
dedicated robotic surgery budgets,
and procurement of new robotic platforms.

This is Route 2: evidence → national evaluation → regional reimbursement structure → adoption.

PATHWAY 3 National HTA (PNHTA):

The New Legitimacy Pathway for MedTech & IVD**

Introduced between 2023 and 2025, Italy’s National HTA Programme for Medical Devices (PNHTA) is a major shift in the European landscape.

It offers:

A single national submission route,
A standardised evidence framework,
An official AGENAS HTA report,
And a shared methodology across the 20 regions.

A positive PNHTA assessment:

accelerates procurement,
aligns regions,
and reduces red tape.

Why PNHTA matters

It is Italy’s first attempt to centralise scientific evaluation of devices and diagnostics — and it is exactly the type of mechanism EU HTA harmonisation (2025–2027) will reward.

Real Example: PNHTA 2025 Robotic Surgery Report

The AGENAS HTA Report (June 2025) on robotic surgery is the clearest proof that PNHTA is real and operational:

It compares robotic vs laparoscopic vs open surgery for urology, gynaecology, and GI surgery.
Evaluates safety, outcomes, workflows, economics, ethics.
Publishes clear recommendations.

Regions immediately used the report to justify:

new tenders for robotic systems,
training investments,
DRG corrections.

This is Route 3: submit once → national credibility → regional acceleration.

PATHWAY 4 Early Access Funding:

Law 648/96 and Special National Mechanisms**

Many assume Italy lacks early-access routes for IVDs — but the opposite is true.

Law 648/96

Originally created for medicines addressing high unmet need, Law 648/96 allows national reimbursement of non-standard or non-marketed technologies, including diagnostics, when:

there is unmet clinical need,
no alternatives exist,
evidence supports utility,
and national reference centres request it.

Real Example: Diagnostic Test Reimbursed Under Law 648/96

The official Law 648/96 lists include diagnostic tests, such as the Test di Ohlsson for lead poisoning, reimbursed nationally at full cost.

This proves the mechanism is legitimate — and can be activated for rare disease diagnostics, oncology panels, advanced infectious disease assays, and high-impact innovations.

Special 5% Fund

Italy also maintains a national 5% innovation fund, historically used for orphan therapies but also applied to diagnostics with:

severe disease burden,
high mortality,
rapid progression,
and strong early evidence.

This is Route 4: rare but powerful → national funding before formal reimbursement exists.

Why These Four Pathways Matter

Together, these four channels dismantle the old myth that “Italy has no reimbursement for diagnostics”.

In reality:

Pathway 1 gives you fast entry.
Pathway 2 gives you durable reimbursement.
Pathway 3 gives you national legitimacy.
Pathway 4 gives you high-impact early access.

The smartest companies combine two or three at the same time, creating pressure from both regional providers and national evaluators.

This is how Italy works now.
This is why it has become one of Europe’s most interesting — and strategically valuable — markets for MedTech and diagnostics.

The Regional Playbook:

How Lombardy, Emilia-Romagna, Veneto, Tuscany and Lazio Actually Decide**

If Italy’s national agencies define the rules of the game, the 20 regions decide who gets to play.
For MedTech, diagnostics and digital health, Italy is not one market — it is 20 overlapping markets, each with its own personality, budgetary pressures, clinical networks and innovation appetite.

Understanding regional behaviour is not optional.
It is Italy’s real reimbursement system.

Below is the playbook the most successful companies follow — and the five regions that shape almost every national trend.

Lombardy: The Fast Adopter (and the Region Everyone Watches)

Lombardy is Italy’s economic engine and its most technologically progressive health ecosystem.

Why Lombardy is essential

Highest concentration of IRCCS research hospitals
Italy’s strongest hubs for oncology, cardiology, microbiology and surgical innovation
The most sophisticated regional procurement processes
High clinical influence across the rest of the country

How Lombardy decides

Lombardy is driven by clinical excellence and operational logic rather than pure pricing. It is the region where:

Robotic platforms gain their first procedural volume
AI radiology tools are piloted at scale
Advanced diagnostics (especially genomic oncology) are adopted early
Workflow-transforming IVDs build their first Italian RWD datasets

If you win in Lombardy, two things happen:

You generate Italian real-world evidence that no other region can dispute.
Other regions assume: “If Lombardy has it… we should evaluate it.”

This is the closest Italy has to a “lighthouse region”.

Emilia-Romagna The Evidence Region

If Lombardy is the innovator, Emilia-Romagna is the scientist.
This region has one of the most mature regional HTA systems in Italy.

Why Emilia-Romagna matters

The region requires clear evidence of organisational benefit for most new technologies
Leading academic centres (Bologna, Modena, Parma, Ferrara)
High clinician involvement in evaluation committees
Deep expertise in microbiology, pathology, infectious disease and orthopaedics

How Emilia-Romagna decides

Emilia-Romagna rewards:

structured cost–consequence analyses
time-to-result improvements
workflow optimisation
patient safety gains
reduction in inappropriate admissions
ICU avoidance

This is the region where your HTA-ready dossier matters most.

If you can convince Emilia-Romagna, you effectively validate your technology for the Italian scientific community.

Veneto: The Efficiency Powerhouse

Veneto runs one of Europe’s most efficient health systems — stable budgets, high outpatient capacity, strong primary care integration.

Why Veneto is crucial

Among the fastest regions for outpatient diagnostic tariff adoption
Strong digital health pilots (especially telemonitoring and chronic care)
Excellent microbiology and emergency medicine networks
Highly organised procurement with predictable cycles

How Veneto decides

Veneto responds to:

faster diagnostic turnaround
improved outpatient management
reduction in hospitalisations
technologies that improve continuity of care

If your diagnostic helps move care upstream (e.g., UTI, AMR, sepsis triage, chronic disease screening), Veneto is one of the best early adopters.

Tuscany: The Strategic Procure-First Region

Tuscany is the region that proved something important:
procurement can drive innovation faster than any national tariff.

Why Tuscany is important

Centralised procurement via ESTAR
Strong culture of system-wide purchasing
Very effective at multi-hospital tenders
High willingness to pursue innovative technologies if the case is strong

How Tuscany decides

Tuscany cares about system economics:

ICU usage
antibiotic stewardship
ED congestion
length of stay
lab workflow

Real Case Example — Rapid AST Tender (2024)

Tuscany’s €2.63m tender for rapid AST across nine hospitals showed that:

a strong organisational case →
a region-wide tender →
immediate multi-hospital adoption.

This region proves one thing with complete clarity:

In Italy, procurement is reimbursement — if the region wants your technology.

Lazio: The Political and Innovation Hub

Lazio is home to Italy’s national ministries, AGENAS, major university hospitals, and a rapidly expanding life sciences cluster.

Why Lazio matters

Strong influence on national policy signals
Major innovation budget (over €110m for biotech/MedTech competitiveness)
Leading oncology, radiology, and genomic centres
Key region for digital health and AI pilots

How Lazio decides

Lazio is often the testing ground for:

digital therapeutics legislation,
remote monitoring pilots,
high-complexity diagnostic pathways,
telemedicine and AI initiatives supported by national funds.

Winning Lazio creates visibility among national stakeholders — AGENAS, Ministry of Health, AIFA — and signals that your technology fits Italy’s long-term innovation agenda.

The Rule Behind All Five Regions: Italy Moves by Domino Effect

Italy does not change through national decree — it changes through regional momentum.

When two of five anchor regions adopt an innovation (typically Lombardy + Emilia-Romagna or Tuscany + Veneto), three things happen:

Other regions copy the evaluation to avoid falling behind.
National scientific societies begin referencing the technology.
AGENAS takes interest, accelerating PNHTA relevance and DRG/LEA discussions.

This is why your Italian strategy must never start with:

“How do we get a national code?”

It must start with:

“Which two regions will create the national domino effect?”

Get those right — and Italy becomes one of the most predictable markets in Europe.

What Evidence Italy Actually Responds To

(And Why Most Companies Get This Completely Wrong)**

If there is one mistake almost every MedTech and diagnostics company makes when entering Italy, it is this:
They arrive with a pharma-style evidence package — an elegant RCT, a handful of publications, maybe a cost–utility paper — and assume Italy will applaud.

It won’t.

Italy does not think like NICE.
It does not behave like HAS.
It does not evaluate devices the way AHTA or G-BA does.

Instead, Italy asks a far more grounded, far more pragmatic, and frankly far more clinically relevant question:

“Does this technology make my hospital run better tomorrow morning?”

If your evidence cannot answer that, the national HTA will stall, the regions won’t prioritise you, and procurement committees will quietly pass you over for another year.

Below is the four-part evidence framework Italy actually responds to — the one successful companies already use, and the one most global players overlook.

Workflow Evidence Italy’s Most Underrated Decision Driver

In Italy, workflow evidence isn’t a bonus; it is a currency.
Italian hospitals, especially in the North and Centre, are acutely aware of:

over-capacity emergency departments
ICU shortages
staffing constraints
laboratory backlogs
unplanned surgical cancellations

So when a diagnostic or digital tool shows it can:

reduce diagnostic turnaround time
accelerate decision-making
unblock ED bottlenecks
reduce pre-operative delays
optimise antibiotic timing

…the response is immediate.

Why this matters more in Italy than anywhere else

Italian hospitals operate with extraordinary efficiency under heavy demand.
Any technology that unlocks time — even minutes — is treated as a structural improvement, not a marginal gain.

This is why Tuscany’s rapid AST tender succeeded:
The shortest turnaround time won, not the lowest price.

Economic Evidence Not ICERs, but Cost–Consequence & Budget Impact

Italy does not lean heavily on QALYs or ICERs for devices.
What Italy wants is something much closer to financial physics:

“Show me where the costs move in my system, and why I should care.”

This means:

A. Cost–consequence analysis

Italy prefers a dashboard of impacts:

ICU days avoided
antibiotic days reduced
tests per shift increased
LOS reduction
reduction in hospital-acquired infections
fewer unnecessary admissions

It wants to understand how these effects distribute across departments (ED, ICU, Microbiology, Internal Medicine).

B. Budget impact

Regions need to see how technology affects:

annual operating budgets
procurement cycles
laboratory staffing
DRG margins
cross-departmental costs

A €1 million diagnostic can be funded quickly if it saves €2 million in ICU bed-days.

This is the kind of logic Italy uses daily — and the kind of logic most companies fail to demonstrate.

Clinical Utility Italy Cares About Real Medicine, Not Abstract Statistics

Italy is often caricatured as bureaucratic.
In reality, Italian clinicians care deeply about clinical utility — in the most literal sense:

“Will this test or device change what I do for the patient at the bedside?”

This includes:

earlier diagnosis of sepsis
improved triaging in ED
reduction in unnecessary antibiotics
avoiding invasive procedures
catching deterioration faster
stratifying oncology patients accurately
preventing readmissions

Italy wants proof that the technology supports better clinical judgement, not just statistical superiority.

This is why the AGENAS HTA report on robotic surgery emphasised:

fewer complications
safer intraoperative conditions
improved surgical precision

These aren’t just numbers; they’re clinical realities Italian surgeons can defend in committee rooms.

Real-World Data (RWD) The Passport to Regional Adoption

In Italy, RWD is more than evidence —
it is credibility.

If you have Italian data, you move to the front of the queue.
If you don’t, you remain “interesting” but not “urgent”.

Why RWD matters so much

Italian decision-makers trust:

Italian clinicians
Italian labs
Italian workflows
Italian “esperienza sul campo” (on-the-ground experience)

Even the most prestigious American or German publication can be trumped by:

a six-week pilot in Bologna,
a 100-patient dataset from Bergamo,
or a workflow study from Padua showing minutes saved per shift.

Where to generate RWD

The five anchor regions:

Lombardy (IRCCS: Humanitas, San Raffaele, Niguarda)
Emilia-Romagna (Rizzoli, Bologna University Hospital)
Veneto (Padua, Verona)
Tuscany (Careggi, ESTAR network)
Lazio (Gemelli, Umberto I)

A single pilot in any of these regions can produce:

enough workflow data for procurement
enough clinical utility for PNHTA
enough economic evidence for DRG discussions
enough credibility to convince other regions to follow

This is how Italy truly scales innovation.

Why Most Companies Fail in Italy

Most companies arrive with:

RCTs but no workflow data
Publications but no Italian RWD
Global budget models but not Italian cost inputs
Clinical superiority but no organisational argument
Strong science but weak procurement logic
A beautiful dossier, but not an Italian dossier

They assume reimbursement is a single door, not a four-lane motorway.

Italy rewards the opposite:

operational clarity
region-specific evidence
Italian real-world data
multi-layered value
a simple, defensible story

The companies that win in Italy are not those with the best data on paper, but those with the best Italian evidence package.

The 2025–2026 Playbook:

How to Secure MedTech & IVD Reimbursement in Italy
(A Scientific, Step-by-Step Strategy for Real-World Success)**

Most European reimbursement pathways follow a recognisable pattern: evidence generation, national HTA submission, tariff assignment, hospital adoption.
Italy does not.
Italy in 2025–2026 operates through a four-axis reimbursement architecture — regional procurement, national tariffing, national HTA, and early-access channels — that must be navigated in parallel, not sequentially.

Below is the scientifically grounded, execution-ready strategy that works in Italy today.
It is not theoretical.
It is built from real tenders, real HTA decisions, and real adoption patterns across Lombardy, Emilia-Romagna, Veneto, Tuscany and Lazio.

STEP 1 Map the Clinical Pathway Using Italian Data

(Where does your technology actually change outcomes?)**

Italy responds to pathway science, not marketing narratives.

Before you approach any region, you must define:

Which clinical steps change?
(earlier pathogen ID, faster surgical workflow, improved oncology stratification, higher ED throughput)
Which clinical endpoints move?
(LOS reduction, antibiotic optimisation, ICU avoidance, reduction in ED revisits)
Where does the technology operate?
(Microbiology, ED triage, peri-operative theatre, oncology molecular labs, cardiology diagnostics)
Which guidelines will eventually use it?
(FISM, AIOM, SIMEU, SIMeL, SItI)

Italy does not reward abstract superiority.
It rewards pathway-integrated, system-level improvement.

SEO Keywords: Italian clinical pathways, diagnostic turnaround, LOS reduction, ICU avoidance, antibiotic stewardship, Italian guidelines.

STEP 2 Generate an Italian Cost–Consequence Model

(Italy runs on economic physics, not QALYs)**

Italy’s decision-making is built on economic reality, not hypothetical utilities.
Your model must consider:

cost per ICU day
cost of ED congestion
incremental cost per microbiology shift
antibiotic-days avoided
operating theatre minutes
DRG levers (profit margins, case-mix penalties, avoidable complications)

This is the model that convinced Tuscany to fund rapid AST.
This is the model that justified DRG recalibrations for robotic surgery.

SEO Keywords: Italy budget impact model, cost–consequence Italy, DRG Italy, ICU cost Italy, hospital economics Italy, Italian MedTech modelling.

STEP 3 Choose Two Anchor Regions

(Italy moves by domino effect, not national instruction)**

To win Italy, you do not need 20 regions.
You need two of the big five:

Lombardy (clinical influence + IRCCS network)
Emilia-Romagna (HTA discipline + evidence credibility)
Veneto (outpatient efficiency + strong lab networks)
Tuscany (procurement-driven innovation across networks)
Lazio (national visibility + digital health pilots)

Once two adopt, others move reflexively — a phenomenon well-documented in hospital procurement behaviour since 2018.

SEO Keywords: Lombardy procurement, Emilia-Romagna HTA, Veneto diagnostics, Tuscany ESTAR tender, Lazio digital health.

STEP 4 Launch a Mini-HTA Pilot

(The fastest way to generate Italian legitimacy)**

Italy excels at mini-HTA — structured, hospital-level HTA that focuses on:

organisational impact
workflow metrics
staff time and capacity
clinical utility
direct and indirect costs
patient safety improvements

A mini-HTA becomes the anchor document used by:

regional procurement teams,
PNHTA evaluators,
hospital directors,
clinical champions,
and national policy stakeholders.

This is the scientific bridge between innovation and reimbursement.

SEO Keywords: mini-HTA Italy, Italian hospital HTA, organisational impact Italy, PNHTA evidence, workflow analysis Italy.

STEP 5 Build RWD in Two Clinical Networks

(Real-world Italian data outranks any foreign publication)**

Italy places extraordinary weight on local real-world performance.

Generate RWD in:

a major IRCCS hospital (e.g., Humanitas, San Raffaele, Gemelli, Rizzoli)
a regional network (e.g., Veneto microbiology cluster, Tuscany ESTAR, Emilia-Romagna surgical centres)

Collect:

turnaround times
admission avoidance
surgical time saved
antibiotic changes
clinical decision modifications
staff workflow metrics

With RWD, you now have the core evidence for:

regional tenders
PNHTA national HTA
DRG recalibration requests
LEA inclusion arguments
clinician advocacy
national guideline positioning

SEO Keywords: RWD Italy, real-world evidence diagnostics Italy, Italian hospital pilots, workflow RWD, Italian multicentre data.

STEP 6 Submit to PNHTA (AGENAS) Early

(National HTA creates scientific authority across 20 regions)**

PNHTA (National HTA Programme for Medical Devices) is now the epicentre of national legitimacy.

A PNHTA submission should include:

mini-HTA results
Italian RWD
cost–consequence model (Italian inputs)
organisational evidence
patient safety impact
clinician testimonials
projected DRG interactions
regional pilot summaries

A positive PNHTA report:

accelerates regional adoption
justifies DRG recalibration
anchors LEA discussions
validates innovation for national scientific societies
elevates your technology above competing tenders

SEO Keywords: PNHTA Italy, AGENAS HTA, Italian medical device HTA, national HTA Italy, PNHTA submission guide.

STEP 7 Advance DRG Recalibration or LEA Inclusion

(The pathway to structural, long-term reimbursement)**

With strong RWD and PNHTA support, you can now pursue formal national reimbursement through:

A. DRG Recalibration

Used when your device or diagnostic is integrated in inpatient care.

You argue:

reduced complications,
improved clinical outcomes,
changed procedure characteristics,
altered resource utilisation.

This is how robotic surgery gained long-term tariff recognition.

B. LEA Inclusion

Used for outpatient diagnostics, screening programmes, chronic disease tools, digital health pathways.

LEA inclusion makes reimbursement:

national,
mandatory,
protected from regional budget cuts.

SEO Keywords: DRG recalibration Italy, LEA inclusion Italy, hospital reimbursement Italy, structural funding Italy.

STEP 8 Scale Through Regional Procurement

(The final step — but not the last)

Once:

two anchor regions adopt,
PNHTA validates,
RWD supports the case,
DRG/LEA moves begin,

…the rest of Italy follows a predictable adoption cascade.

Regions replicate each other’s:

tender specifications,
evaluation criteria,
clinical justifications,
pilot designs,
stakeholder mappings.

This is the Italian domino model of MedTech diffusion.

SEO Keywords: regional procurement Italy, ESTAR tender, Lombardy tenders, Emilia-Romagna HTA procurement, Veneto device reimbursement.

What This Strategy Achieves

You transform Italy from a slow, bureaucratic enigma
into a scientifically structured, evidence-responsive, multi-pathway access market.

You unlock:

rapid early adoption
national credibility
multi-region scaling
long-term reimbursement stability
diagnostic and digital health pathways previously considered “non-existent”

You become part of the quiet revolution reshaping Italian reimbursement.

Conclusion:

Why Italy Is Becoming Europe’s Most Strategic MedTech Market (2025–2026)**

For two decades, Italy has been treated as an awkward afterthought in European market access — a country to approach late, quietly, cautiously, and only after France, Germany and the UK had formally opened their doors.

But the story of Italy in 2025–2026 is not the story of the past.
It is the story of a country undergoing a quiet structural transformation in how it evaluates, funds and adopts medical technologies.

Only now, when you zoom out, does the pattern become visible.

A country once dismissed as opaque now offers four distinct, predictable pathways

Where global companies once saw fragmentation, they now find architecture:

Regional procurement delivering fast adoption for diagnostics and applied technologies;
National tariffing (LEA & DRG recalibration) offering durable, structural reimbursement;
PNHTA, a national HTA programme providing unified scientific evaluation;
Early-access funding via Law 648/96 and innovation funds that accelerate availability for high-need patients.

This is not chaos — it is a multi-lane access system.
The problem was never absence of pathways; it was absence of visibility.

A health system once considered too regional is now strategically advantageous

Italy’s decentralisation — long described as a weakness — is becoming its most important strength.

Why?

Because regional systems:

adopt faster,
respond to real clinical pressure,
innovate without waiting for national codes,
and produce rich real-world datasets.

Tuscany can fund rapid AST before a national tariff exists.
Lombardy can champion robotics and precision diagnostics.
Veneto can drive outpatient diagnostic reform.
Emilia-Romagna can create evidence benchmarks.
Lazio can trial digital therapeutics and AI.

Innovation does not need to pass through a single narrow gate.
It can enter the system through multiple doors at once.

A decision-making culture once misunderstood is now one of Europe’s most rational

Italy does not obsess over ICER thresholds or theoretical QALYs.
It cares about:

hospital workflow,
diagnostic accuracy,
ICU utilisation,
antimicrobial resistance,
cancer stratification,
ED throughput,
and organisational resilience.

This is not anti-scientific.
It is deeply scientific — grounded in the realities of healthcare delivery, patient flow, and system-level performance.

Italy’s most powerful question remains:

“Does this technology make our system work better tomorrow morning?”

If you can answer that convincingly, Italy will fund you.

A market once considered slow is now becoming one of the fastest in Europe

Italy rewards:

real-world evidence,
meaningful organisational improvements,
clinically actionable diagnostics,
technologies that save hours rather than years,
solutions that lower ICU, ED or surgical burden,
tools that fill gaps in infectious disease, oncology, peri-operative care and chronic disease management.

The result?

Technologies that take 18–36 months to gain reimbursement in Germany or France can secure:

regional procurement within 3–9 months,
PNHTA visibility within 12–18 months,
national tariff upgrades within 18–36 months,
real-world scaling across 20 regions far faster than previously imagined.

Italy is no longer the black box — it is the opportunity

Italy is becoming the European market where:

diagnostics prove their clinical utility,
MedTech platforms generate their most compelling RWD,
AI tools demonstrate real-world safety and workflow impact,
digital therapeutics find their policy footing,
and companies build long-term relationships with regions that act decisively.

In 2025–2026, Italy is transforming from a “wait-and-see” market into a launch-first market for:

rapid infectious disease diagnostics,
oncology genomic panels,
surgical robotics,
AI-enabled decision tools,
remote monitoring,
chronic disease applications,
peri-operative technologies,
and new digital health models.

The final truth

Success in Italy is not reserved for the largest companies or those with the longest publication lists.
It belongs to those who understand:

how the system works,
who the decision-makers are,
what evidence matters,
and which pathways can be activated in parallel.

Italy is not confusing.
Italy is not impenetrable.
Italy is not slow.

Italy is a scientific, evidence-responsive, strategically navigable market undergoing one of the most important MedTech reimbursement transformations in Europe.

It is no longer the country you enter last.
It is the country you enter first if you know how.

1. National HTA & AGENAS References

(If needed, I can extract the PDF summary for embedding.)

2. Italian Legislation & Early Access Funding

Law 648/96 – Early Access Funding Mechanism (AIFA)

Official text and determinations:
🔗 https://www.aifa.gov.it/en/web/guest/normativa-legge-648-96

Example of Diagnostic Test Reimbursed Under 648/96

Official determination-based listing including the “Test di Ohlsson” (diagnostic reference):
🔗 https://www.aboutpharma.com/blog/2011/07/18/determina-aifa-legge-648-96/

(Full text of determinations available in AIFA archives.)

3. Regional Procurement & Real Italian Case Studies

Tuscany (ESTAR) — Rapid AST Regional Tender (2024)

Official tender summary (in Q-linea regulatory announcement):
🔗 https://qlinea.com/blog/2024/03/15/q-linea-participates-in-tender-in-tuscany/

(This is the cleanest public reference; underlying documents are in the ESTAR procurement archive.)

ESTAR – Regional Procurement Portal (Tuscany)

Searchable regional procurement notices for medical devices & diagnostics:
🔗 https://www.estar.toscana.it/bandi-di-gara

ARCS Procurement (Friuli Venezia Giulia)

Example of regional procurement structure (useful for comparing models):
🔗 https://arcs.sanita.fvg.it/it/gare-appalti

Lombardy Procurement (ARIA S.p.A.)

Central purchasing body for Lombardy — innovation, diagnostics, capital equipment:
🔗 https://www.ariaspa.it

4. Italian Regional HTA Bodies (Mini-HTA & Regional Evaluation)

Emilia-Romagna Regional HTA Programme

Official HTA unit producing Mini-HTA and regional evaluations:
🔗 https://assr.regione.emilia-romagna.it/it/valutazione/hta

Veneto Regional HTA (Scuola Veneto HTA)

Evaluations & organisational impact analyses:
🔗 https://www.venetohta.it

Tuscany – Regional Health Agency (ARS Toscana)

Clinical and economic evaluations relevant to diagnostics and public health:
🔗 https://www.ars.toscana.it

Lazio – Agenzia Sanitaria Regionale (LAS)

Digital health pilots and evaluation reports:
🔗 https://www.regione.lazio.it/salute

5. National Reimbursement, LEA & DRG Sources

LEA (Livelli Essenziali di Assistenza) – Ministry of Health

National reimbursement list for outpatient care, diagnostics & procedures:
🔗 https://www.salute.gov.it/portale/lea/homeLea.jsp

National DRG System — Italian DRG Manual (SDO)

Official DRG classification and tariff documents:
🔗 https://www.salute.gov.it/portale/documentazione/p6_2_8_1.jsp?lingua=italiano&id=290

National Tariff Catalogue (Nomenclatore Tariffario)

Outpatient tariffs, diagnostics, laboratory procedures:
🔗 https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2223

6. Scientific & Policy References

Tarricone et al. — Establishing a National HTA Programme for Medical Devices in Italy

Health Policy (Elsevier):
🔗 https://www.sciencedirect.com/science/article/pii/S0168851021000750

EIT Health — Digital Therapeutics: The Italian Landscape (2023)

Official position paper (digital health reimbursement evolution):
🔗 https://eithealth.eu/wp-content/uploads/2023/07/Position-Paper-EIT-Innostars-def-Eng.pdf

Italian Ministry of Health — National Digital Health Strategy (PNRR Missione 6)

Digital health and telemedicine reforms 2023–2026:
🔗 https://www.salute.gov.it/portale/pnrr/homePnrr.jsp

7. Additional High-Authority Sources for Evidence & Market Access

Agenzia per l’Italia Digitale (AgID) — Digital Health Standards & Interoperability

🔗 https://www.agid.gov.it/it/agenzia/agenda-digitale/sanita-digitale

Istat & GIMBE Foundation — Health System Performance Data

For epidemiology, hospital burden & regional differences:
🔗 https://www.istat.it
🔗 https://fondazionegimbe.org

Italian Society of Medical Laboratory Specialists (SIME) Guidelines

🔗 https://www.simeitalia.it

Italian Society of Infectious Diseases (SIMIT) — Clinical Guidance

🔗 https://www.simit.org

The Truth About Italian Reimbursement: